학술논문
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Document Type
article
Author
Source
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Subject
Language
English
ISSN
2051-1426